Trials / Terminated
TerminatedNCT00795353
Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Amevive Wisdom Acquired Through Real-world Evidence - 2 (A.W.A.R.E.-2) Program: Long-Term Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 64 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a prospective, multi-centre, observational study designed to assess the long-term effectiveness and safety of alefacept in subjects with moderate to severe chronic plaque psoriasis.
Detailed description
Study includes a bio-marker sub-study to determine differences in responders vs. non-responders. Additional consent is required for the sub-study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amevive exposure | Commercial alefacept prescribed by Physician |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2008-11-21
- Last updated
- 2013-02-28
Locations
21 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00795353. Inclusion in this directory is not an endorsement.